• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Page 4 > Press

In the media

Page 4 > Press

In the media

filters

Type & Disease
Topic
Location
Date Range
Type & Disease

By Type

news type

By Disease

diseases

Topic

By Topic

topic type

Location

By Location

location-news

Date Range

By Year

date range filter – slider
1999 — 2026

Results

No results found. Please try using different filter option(s).

Scientific articles
16 Nov 2026

An AI-powered smartphone application for universal and standardized reading and interpretation of lateral flow assays

PLOS Global Public Health
Scientific articles
10 Nov 2026

Evaluation of the performance of rapid diagnostic tests in point-of-care conditions for serological diagnosis of chagas disease in pregnant women in Colombia

PLOS Neglected Tropical Diseases
Publications
6 Nov 2026

Extreme heat and climate-sensitive infectious diseases

Scientific articles
3 Nov 2026

Transcriptomic and proteomic analysis of quiescent epimastigotes as a resource for investigating Trypanosoma cruzi persistence

Communications Biology
News
2 Nov 2026

Project to develop dengue treatment pre-selected by the Global Coalition for Local and Regional Production, Innovation, and Equitable Access

close up of a scientist holding tools they are wearing blue gloves
Press releases
29 Oct 2026

DNDi welcomes GHIT Fund’s support for innovative approaches to improve success in Chagas disease drug discovery with Nagasaki University, the University of Dundee, and Eisai 

Scientific articles
27 Oct 2026

Strengthening health systems and clinical development capacities through effective partnerships: a case study of DNDi’s collaboration with the Leishmaniasis Research and Treatment Center in Ethiopia (2003–2022)

Frontiers in Tropical Diseases
Press releases
27 Oct 2026

Kenya becomes first African country to join the Dengue Alliance

Scientific articles
26 Oct 2026

Efficacy and safety of oxfendazole in adults with Trichuris spp. infection in Pemba Island, Tanzania: a double-blind, phase 2a, randomised controlled trial

eClinicalMedicine
Scientific articles
22 Oct 2026

Deconvoluting the mode of action of antileishmanial aminopyrazoles through chemical mutagenesis

Nature communications
Scientific articles
10 Oct 2026

Rethinking Clinical Trial Design to Accelerate Therapeutics for Arboviral Epidemics

Open Forum Infectious Diseases
News
9 Oct 2026

DNDi 2026 Projects of the Year recognize teams and partners for their work to advance an open-science antiviral for future coronavirus pandemics and a single-dose treatment for sleeping sickness

Scientific articles
9 Oct 2026

A Perspective on Biomarkers, Candidates for Surrogate End Points to Accelerate Successful Development of New Antiparasitic Agents for the Treatment of Chronic Chagas Disease

ACS Infectious Diseases
Press releases
6 Oct 2026

Ghana’s KNUST and DNDi partner to accelerate drug discovery for neglected diseases in Africa

Scientific articles
5 Oct 2026

Winning the endgame against sleeping sickness: Efficacy profiling of acoziborole against African trypanosomes with the focus on Trypanosoma brucei rhodesiense

PLoS Neglected Tropical Diseases
Statements
25 Sep 2026

DNDi intervention at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response at the 81st UN General Assembly

loading
Loading...
Sci Dev Net logo
In the media
12 Mar 2026

Single-dose sleeping sickness drug set for approval

Nature reviews
El Pais logo
In the media
11 Mar 2026

Tres pastillas para eliminar la enfermedad del sueño en un contexto de recortes globales en ayuda al desarrollo

El País
RFI logo
In the media
10 Mar 2026

Entretien avec Dr Hélène Mahenzi à propos d’un nouveau médicament développé contre la maladie du sommeil

RFI Priorité Santé
El Pais logo
In the media
9 Mar 2026

Falta de medicamentos, centros médicos destruidos y recortes: cómo la guerra en Sudán ha golpeado a las enfermedades más olvidadas

El País
Nature Africa logo
In the media
3 Mar 2026

Single-dose treatment approved for sleeping sickness

Nature Africa
Nature Africa logo
In the media
3 Mar 2026

Traitement à dose unique approuvé pour la maladie du sommeil

Nature Africa
La Razón
In the media
2 Mar 2026

Europa da el visto bueno a una terapia más sencilla contra la enfermedad del sueño

La Razon
Science logo
In the media
27 Feb 2026

‘Truly spectacular’ drug for sleeping sickness simplifies treatment, raising hopes for eradication

Science
France 24 logo
In the media
27 Feb 2026

La maladie du sommeil bientôt éliminée ? Feu vert européen à un nouveau traitement

France 24
Le Monde logo
In the media
27 Feb 2026

Maladie du sommeil : l’autorisation européenne d’un nouveau traitement laisse entrevoir une élimination de la maladie d’ici à 2030

Le Monde
Bloomberg logo
In the media
27 Feb 2026

New pill has potential to eliminate deadly sleeping sickness

Bloomberg
AP logo
In the media
27 Feb 2026

New sleeping sickness pill gets nod, paving the way for use in Africa

Associated Press
KBC logo
In the media
27 Feb 2026

Breakthrough single-dose treatment for sleeping sickness gets EU nod

KBC
In the media
27 Feb 2026

Single-dose sleeping sickness pill clears major EU regulatory milestone

Capital FM
Citizen TV logo
In the media
27 Feb 2026

EMA gives positive opinion for single-dose sleeping sickness medication

Citizen Digital
Fierce Pharma logo, red copy on white background
In the media
27 Feb 2026

After CHMP nod, Moderna CEO applauds EU’s ‘rigorous scientific review’

Fierce Pharma
1 2 … 131 ›

Connect and share

Follow us on social media to stay updated and help us share the stories of neglected patients.  

Twitter Facebook Instagram Youtube Linkedin
EN ESPAÑOL
EM PORTUGUÊS
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license